We are live on ! Find out more
PCM

Penserra Capital Management Portfolio holdings

AUM $8.52B
1-Year Est. Return 37.76%
This Fund
S&P 500
This Quarter Est. Return
+7.88%
1 Year Est. Return
+37.76%
3 Year Est. Return
+116.32%
5 Year Est. Return
+122.1%
10 Year Est. Return
+1,892.45%
AUM
$5.51B
AUM Growth
+$99.7M
Cap. Flow
-$170M
Cap. Flow %
-3.09%
Top 10 Hldgs %
18.48%
Holding
1,445
New
336
Increased
635
Reduced
341
Closed
112

Top Buys

Rank Stock Value
1
AMD icon
Advanced Micro Devices
AMD
+$53.9M
2
PDD icon
Pinduoduo
PDD
+$47.7M
3
LOGC
ContextLogic
LOGC
+$25.5M
4
TDUP icon
ThredUp
TDUP
+$25.1M
5
UPWK icon
Upwork
UPWK
+$24.9M

Top Sells

Rank Stock Value
1
RVLV icon
Revolve Group
RVLV
+$66M
2
NTES icon
NetEase
NTES
+$50.7M
3
TRIP icon
TripAdvisor
TRIP
+$46.2M
4
GRPN icon
Groupon
GRPN
+$44.5M
5
QVCGA
QVC Group Inc Series A
QVCGA
+$43.8M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 30%
2 Technology 24.74%
3 Communication Services 13.13%
4 Financials 5.61%
5 Industrials 4.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYRS
1301
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$7K ﹤0.01%
141
+1
+0.7% +$59
FUSN
1302
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$7K ﹤0.01%
965
+20
+2% +$172
PRTK
1303
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$7K ﹤0.01%
1,070
+20
+2% +$162
SURF
1304
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$7K ﹤0.01%
990
+60
+6% +$462
JNCE
1305
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$7K ﹤0.01%
1,165
+135
+13% +$1.12K
KLDO
1306
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
$7K ﹤0.01%
970
+30
+3% +$213
ABUS icon
1307
Arbutus Biopharma
ABUS
$915M
$6K ﹤0.01%
2,195
+255
+13% +$790
CLLS
1308
Cellectis
CLLS
$285M
$6K ﹤0.01%
430
-5
-1% -$84
IMUX icon
1309
Immunic
IMUX
$195M
$6K ﹤0.01%
50
+1
+2% +$138
OVID icon
1310
Ovid Therapeutics
OVID
$491M
$6K ﹤0.01%
1,545
+105
+7% +$414
XERS icon
1311
Xeris Biopharma Holdings
XERS
$1.37B
$6K ﹤0.01%
1,510
+155
+11% +$592
EIGR
1312
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$6K ﹤0.01%
26
+1
+4% +$250
CBAY
1313
DELISTED
Cymabay Therapeutics
CBAY
$6K ﹤0.01%
1,570
-25
-2% -$111
ORTX
1314
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$6K ﹤0.01%
152
+13
+9% +$724
CHMA
1315
DELISTED
Chiasma, Inc. Common Stock
CHMA
$6K ﹤0.01%
1,320
-10
-0.8% -$38
KMDA icon
1316
Kamada
KMDA
$419M
$5K ﹤0.01%
1,020
-5
-0.5% -$30
KZR
1317
DELISTED
Kezar Life Sciences
KZR
$5K ﹤0.01%
110
+4
+4% +$227
NXTC icon
1318
NextCure
NXTC
$23.8M
$5K ﹤0.01%
53
+2
+4% +$205
UBX
1319
DELISTED
Unity Biotechnology
UBX
$5K ﹤0.01%
125
+4
+3% +$193
BCEL
1320
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$5K ﹤0.01%
685
+5
+0.7% +$51
CABA icon
1321
Cabaletta Bio
CABA
$455M
$4K ﹤0.01%
565
+20
+4% +$197
MNOV icon
1322
MediciNova
MNOV
$66M
$4K ﹤0.01%
1,110
+5
+0.5% +$22
YARW
1323
Yarrow Bioscience, Inc. Common Stock
YARW
$111M
$4K ﹤0.01%
1
– –
RVLP
1324
DELISTED
RVL Pharmaceuticals plc Ordinary Shares
RVLP
$4K ﹤0.01%
1,430
+10
+0.7% +$31
TCDA
1325
DELISTED
Tricida, Inc. Common Stock
TCDA
$4K ﹤0.01%
1,145
+20
+2% +$95
51 52
53
54 55

Similar funds

GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NB
Norinchukin Bank Tokyo, Japan $8.57B AUM 20.17% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
ACM
Advisors Capital Management Ridgewood, New Jersey $8.58B AUM 23.43% 1-Year Est. Return
FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Penserra Capital Management's Q2 2021 Portfolio in Review

As of Q2 2021, Penserra Capital Management held 1,445 positions worth $5.51B, up 1.8% from $5.41B the previous quarter. Its ten largest holdings account for 18% of the portfolio.

Penserra Capital Management withdrew a net $170M in Q2 2021, closing 112 positions and reducing 341 holdings. Its most notable exit was Just Eat Takeaway.com N.V. American Depositary Shares, an estimated $23.3M position sold in full.

By sector, the portfolio is most concentrated in Consumer Discretionary at 30% of assets, down from 33% a quarter earlier, followed by Technology and Communication Services.

Against the trend, Penserra Capital Management opened a new position in ContextLogic worth $28.5M.

  • Penserra Capital Management's largest Q2 2021 buy was ContextLogic: 72,047 shares worth $28.5M.
  • Penserra Capital Management added most to Advanced Micro Devices in Q2 2021, an estimated $53.9M increase.
  • Penserra Capital Management's biggest Q2 2021 reduction was Revolve Group, cutting an estimated $66M.
  • Penserra Capital Management fully exited Just Eat Takeaway.com N.V. American Depositary Shares in Q2 2021, selling an estimated $23.3M.
  • Penserra Capital Management's ten largest holdings make up 18% of its $5.51B portfolio in Q2 2021.
  • Penserra Capital Management opened 336 new positions and closed 112 in Q2 2021.
  • Penserra Capital Management's portfolio value rose 1.8% quarter-over-quarter to $5.51B.

Based on Penserra Capital Management's 13F filing for Q2 2021, filed 12 Aug 2021.